On Aug. 3, 2021, Eli Lilly and Incyte announced results from an additional cohort of 101 adult patients from the COV-BARRIER trial

In this sub-study, patients with COVID-19 on mechanical ventilation or extracorporeal membrane oxygenation (ECMO) who received baricitinib plus standard of care were 46 percent less likely to die by Day 28 compared to patients who received placebo plus standard of care. These findings were consistent with the reduction in mortality observed in the overall COV-BARRIER patient population.